AbClon Inc - Asset Resilience Ratio

Latest as of March 2025: 14.74%

AbClon Inc (174900) has an Asset Resilience Ratio of 14.74% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of AbClon Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩4.86 Billion

≈ $3.29 Million USD Cash + Short-term Investments

Total Assets

₩32.96 Billion

≈ $22.34 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how AbClon Inc's Asset Resilience Ratio has changed over time. See AbClon Inc balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down AbClon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 174900 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩1.86 Billion	5.64%
Short-term Investments	₩3.00 Billion	9.1%
Total Liquid Assets	₩4.86 Billion	14.74%

Asset Resilience Insights

Moderate Liquidity: AbClon Inc has 14.74% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

AbClon Inc Industry Peers by Asset Resilience Ratio

Compare AbClon Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for AbClon Inc (2015–2024)

The table below shows the annual Asset Resilience Ratio data for AbClon Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	45.37%	₩21.86 Billion ≈ $14.82 Million	₩48.18 Billion ≈ $32.65 Million	+6.85pp
2023-12-31	38.53%	₩17.50 Billion ≈ $11.86 Million	₩45.42 Billion ≈ $30.78 Million	-6.13pp
2022-12-31	44.65%	₩24.14 Billion ≈ $16.36 Million	₩54.06 Billion ≈ $36.64 Million	+10.24pp
2021-12-31	34.42%	₩10.27 Billion ≈ $6.96 Million	₩29.83 Billion ≈ $20.21 Million	-14.30pp
2020-12-31	48.72%	₩19.55 Billion ≈ $13.25 Million	₩40.13 Billion ≈ $27.20 Million	-11.83pp
2019-12-31	60.55%	₩28.44 Billion ≈ $19.27 Million	₩46.97 Billion ≈ $31.83 Million	-11.02pp
2018-12-31	71.57%	₩20.54 Billion ≈ $13.92 Million	₩28.70 Billion ≈ $19.45 Million	-10.40pp
2017-12-31	81.97%	₩17.10 Billion ≈ $11.59 Million	₩20.87 Billion ≈ $14.14 Million	+9.25pp
2016-12-31	72.72%	₩11.64 Billion ≈ $7.89 Million	₩16.01 Billion ≈ $10.85 Million	+10.87pp
2015-12-31	61.85%	₩10.00 Billion ≈ $6.78 Million	₩16.17 Billion ≈ $10.96 Million	--

pp = percentage points

About AbClon Inc

KQ:174900 Korea Biotechnology

Market Cap

$408.87 Million

₩603.34 Billion KRW

Market Cap Rank

#13425 Global

#413 in Korea

Share Price

₩31600.00

Change (1 day)

-7.06%

52-Week Range

₩9890.00 - ₩89100.00

All Time High

₩90600.00